Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 3432701, 10 pages
Research Article

Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models

1Department of Pediatrics, University of Tennessee Health Science Center (UTHSC) and Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, TN, USA
2Department of Pediatrics and Hematology-Oncology, Baylor College of Medicine and Texas Children’s Cancer Center, Houston, TX, USA

Correspondence should be addressed to D. Betty Lew; ude.cshtu@weld

Received 10 February 2017; Revised 31 May 2017; Accepted 4 June 2017; Published 1 August 2017

Academic Editor: Ansarullah

Copyright © 2017 D. Betty Lew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.